{
    "clinical_study": {
        "@rank": "112895", 
        "arm_group": {
            "arm_group_label": "Treatment (imatinib mesylate)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have\n      relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of\n      tumor cells by blocking the enzymes necessary for their growth."
        }, 
        "brief_title": "Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood", 
        "condition": [
            "Childhood Desmoplastic Small Round Cell Tumor", 
            "Childhood Synovial Sarcoma", 
            "Gastrointestinal Stromal Tumor", 
            "Lung Metastases", 
            "Recurrent Childhood Soft Tissue Sarcoma", 
            "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", 
            "Recurrent Neuroblastoma", 
            "Recurrent Osteosarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neuroblastoma", 
                "Osteosarcoma", 
                "Sarcoma, Synovial", 
                "Lung Neoplasms", 
                "Neuroectodermal Tumors", 
                "Neuroectodermal Tumors, Primitive", 
                "Sarcoma", 
                "Gastrointestinal Stromal Tumors", 
                "Desmoplastic Small Round Cell Tumor", 
                "Sarcoma, Ewing's", 
                "Neuroectodermal Tumors, Primitive, Peripheral"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the response rate of patients with relapsed or refractory pediatric solid\n      tumors treated with imatinib mesylate.\n\n      II. Determine the toxicity of this drug in these patients. III. Determine the time to\n      progression in patients treated with this drug. IV. Determine the pharmacokinetics of this\n      drug in these patients. V. Correlate response with c-kit and platelet-derived growth factor\n      receptor expression in patients treated with this drug.\n\n      OUTLINE: This is a multicenter study.  Patients are stratified according to  disease\n      (Ewing's sarcoma/primitive neuroectodermal tumor vs osteosarcoma vs neuroblastoma vs other).\n\n      Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat\n      every 28 days for up to 2 years in the absence of disease progression or unacceptable\n      toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed solid tumors including  the following:\n\n               -  Ewing's sarcoma\n\n               -  Bone or soft tissue primitive neuroectodermal tumor\n\n               -  Osteosarcoma\n\n               -  Neuroblastoma\n\n               -  Desmoplastic small round cell tumor\n\n               -  Synovial cell sarcoma\n\n               -  Gastrointestinal stromal tumor (GIST)\n\n          -  Metastatic pulmonary disease eligible\n\n               -  No pleural effusion of any size or definite radiologic evidence of pleural-based\n                  disease\n\n          -  Recurrent or refractory to conventional therapy\n\n               -  GIST eligible at initial presentation\n\n          -  Tumor tissue blocks must be available\n\n          -  At least 1 measurable lesion\n\n               -  At least 20 mm by conventional techniques\n\n               -  At least 10 mm by spiral CT scan\n\n               -  Lesions assessable only by radionuclide scan are not considered measurable\n\n          -  Performance status - Lansky 50-100% (\u2264 10 years of age)\n\n          -  Performance status - Karnofsky 50-100% (> 10 years of age)\n\n          -  At least 2 months\n\n          -  Absolute neutrophil count \u2265 1,000/mm^3*\n\n          -  Platelet count \u2265 75,000/mm^3* (transfusion independent)\n\n          -  Hemoglobin \u2265 8.0 g/dL* (RBC transfusions allowed)\n\n          -  Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n\n          -  ALT \u2264 2.5 times ULN\n\n          -  INR < 1.5\n\n          -  PTT \u2264 ULN\n\n          -  Fibrinogen \u2265 lower limit of normal\n\n          -  Creatinine normal for age\n\n          -  Glomerular filtration rate \u2265 70 mL/min\n\n          -  No uncontrolled infection\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective barrier contraception\n\n          -  At least 1 week since prior biologic therapy or immunotherapy and recovered\n\n          -  At least 1 week since prior growth factors\n\n          -  No concurrent immunomodulating agents\n\n          -  At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)\n             and recovered\n\n          -  No concurrent chemotherapy\n\n          -  No concurrent steroids\n\n          -  Recovered from prior radiotherapy\n\n          -  At least 2 weeks since prior local palliative radiotherapy (small port)\n\n          -  At least 3 months since prior craniospinal radiotherapy or radiotherapy to 50% or\n             more of pelvis\n\n          -  At least 6 weeks since other prior substantial bone marrow radiation\n\n          -  No concurrent radiotherapy during first course of treatment\n\n          -  Concurrent palliative radiotherapy to local painful lesions allowed after first\n             course of treatment provided there is no evidence of disease progression and at least\n             1 measurable lesion remains outside radiation port\n\n          -  No concurrent therapeutic doses of warfarin\n\n          -  No concurrent anticonvulsants that induce the cytochrome p450 enzyme system (e.g.,\n             phenytoin, carbamazepine, and phenobarbital)\n\n          -  Concurrent benzodiazepines and gabapentin allowed\n\n          -  Concurrent low-molecular weight heparin allowed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00030667", 
            "org_study_id": "NCI-2012-01869", 
            "secondary_id": [
                "NCI-2012-01869", 
                "CDR0000069187", 
                "COG-ADVL0122", 
                "ADVL0122", 
                "ADVL0122", 
                "U10CA098543"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (imatinib mesylate)", 
                "description": "Given orally", 
                "intervention_name": "imatinib mesylate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CGP 57148", 
                    "Gleevec", 
                    "Glivec"
                ]
            }, 
            {
                "arm_group_label": "Treatment (imatinib mesylate)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (imatinib mesylate)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Imatinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Arcadia", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91006-3776"
                }, 
                "name": "Children's Oncology Group"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors", 
        "overall_official": {
            "affiliation": "Children's Oncology Group", 
            "last_name": "Mason Bond", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "95% confidence interval will be computed.", 
                "measure": "Response rate, determined using the RECIST criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Toxicity reported using the CTC version 2.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "removed_countries": {
            "country": [
                "Australia", 
                "Canada", 
                "Netherlands", 
                "New Zealand", 
                "Puerto Rico", 
                "Switzerland"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00030667"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Calculated by the method of Kaplan and Meier.", 
            "measure": "Time to disease progression", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 years"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 2002", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }, 
    "geocoordinates": {
        "Children's Oncology Group": "34.14 -118.035"
    }
}